Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Targeted Treatment in Chronic Inflammatory Arthritis
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Targeted Treatment in Chronic Inflammatory Arthritis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: 30 August 2025 | Viewed by 1513

Special Issue Editors

Dr. Cinzia Rotondo

E-Mail Website
Guest Editor
Rheumatology Unit, Università degli Studi di Foggia, 71122 Foggia, Italy
Interests: systemic sclerosis; rheumatoid arthritis; psoriatic arthritis
Special Issues, Collections and Topics in MDPI journals
Dr. Simone Parisi

E-Mail Website
Guest Editor
Rheumatology Unit, AOU Città Della Salute e della Scienza di Torino, 10126 Turin, Italy
Interests: rheumatology; rheumatoid arthritis; psoriatic arthritis; ostarthritis
Special Issues, Collections and Topics in MDPI journals
Dr. Simone Perniola

E-Mail Website
Guest Editor
1. Immunology Research Core Facility, Gemelli Science and Technology Park (GSTeP), Fondazione Policlinico Universitario A. Gemelli IRCCS—Rome, 00168 Rome, Italy
2. Division of Clinical Immunology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore—Rome, 00168 Rome, Italy
Interests: clinical rheumatology; inflammation; rheumatic diseases; autoantibodies; knee osteoarthritis; rheumatology; autoimmunity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue of the Journal of Clinical Medicine (JCM) focuses on “Targeted Treatment in Chronic Inflammatory Arthritis” and aims to provide a comprehensive overview of the latest advancements in targeted therapies within the scope of clinical medicine. The primary objective of this Special Issue is to present original research articles, systematic reviews, and meta-analyses that explore the efficacy, safety, and clinical outcomes of targeted treatment approaches in chronic inflammatory arthritis.

Specific areas of interest for this Special Issue include, but are not limited to, the following:

  1. Evaluation of the effectiveness and long-term outcomes of targeted therapies in different types of chronic inflammatory arthritis.
  2. Assessment of the impact of targeted therapies on disease progression, remission rates, quality of life, and comorbidities in patients with chronic inflammatory arthritis.
  3. Comparative studies analyzing the efficacy and safety profiles of different targeted treatment modalities.

We invite researchers, clinicians, and scholars in the field of clinical medicine to contribute their valuable insights and findings to this Special Issue. Together, we can advance our understanding of targeted treatment options and improve the management of chronic inflammatory arthritis.

Dr. Cinzia Rotondo
Dr. Simone Parisi
Dr. Simone Perniola
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatoid arthritis
  • psoriatic arthritis
  • ankylosing spondylitis
  • spondyloarthritis
  • disease-modifying antirheumatic drugs (DMARDs)
  • personalized medicine
  • immunomodulatory therapies
  • patient outcomes
  • combination therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 1479 KiB  
Review
Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease
by Piotr Kawczak, Igor Jarosław Feszak and Tomasz Bączek
J. Clin. Med. 2025, 14(8), 2605; https://doi.org/10.3390/jcm14082605 - 10 Apr 2025
Viewed by 634
Abstract
Background/Objectives: Inflammatory arthritides includes a range of joint disorders, such as osteoarthritis and rheumatoid arthritis, as well as inflammatory conditions like gout and lupus. This review investigates the pathophysiology, therapeutic challenges, and evolving treatment landscape of arthritis, with a particular focus on [...] Read more.
Background/Objectives: Inflammatory arthritides includes a range of joint disorders, such as osteoarthritis and rheumatoid arthritis, as well as inflammatory conditions like gout and lupus. This review investigates the pathophysiology, therapeutic challenges, and evolving treatment landscape of arthritis, with a particular focus on the clinical roles of rituximab, apremilast, and upadacitinib. Methods: A comprehensive analysis was undertaken to evaluate the current clinical application, therapeutic efficacy, and safety profiles of selected biosimilar and targeted synthetic disease-modifying antirheumatic drugs (bsDMARDs and tsDMARDs). This overview placed particular emphasis on three key agents—rituximab, apremilast, and upadacitinib—each exemplifying distinct immunomodulatory mechanisms. By focusing on these agents, the analysis highlights the evolving landscape of targeted therapies in rheumatology and underscores the importance of personalized treatment selection based on the disease phenotype, prior therapeutic responses, and comorbid conditions. Results: Rituximab, apremilast, and upadacitinib each present valuable therapeutic options for patients who have shown inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) or nonsteroidal anti-inflammatory drugs (NSAIDs). Conclusions: Despite the complexity and heterogeneity of arthritis, agents like rituximab, apremilast, and upadacitinib have expanded the therapeutic possibilities in treating this disease and improved its management. Continued research is essential to optimize patient-specific treatment strategies and explore novel molecular targets. Full article
(This article belongs to the Special Issue Targeted Treatment in Chronic Inflammatory Arthritis)
►▼ Show Figures

Figure 1

23 pages, 2414 KiB  
Review
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment
by Piotr Kawczak, Igor Jarosław Feszak and Tomasz Bączek
J. Clin. Med. 2025, 14(6), 2107; https://doi.org/10.3390/jcm14062107 - 19 Mar 2025
Viewed by 571
Abstract
Background/Objectives: Arthritis encompasses a range of joint-related conditions, including osteoarthritis and rheumatoid arthritis, along with inflammatory diseases such as gout and lupus. This research study explores the underlying causes, challenges, and treatment options for arthritis, aiming to enhance the effectiveness of therapies. [...] Read more.
Background/Objectives: Arthritis encompasses a range of joint-related conditions, including osteoarthritis and rheumatoid arthritis, along with inflammatory diseases such as gout and lupus. This research study explores the underlying causes, challenges, and treatment options for arthritis, aiming to enhance the effectiveness of therapies. Methods: This research study evaluated current treatment strategies and examined the effectiveness of selected biological disease-modifying antirheumatic drugs (bDMARDs), i.e., abatacept, golimumab, and sarilumab, with a focus on emerging drug classes and their distinct mechanisms of action. Results: Biologic DMARDs like abatacept, golimumab, and sarilumab offer hopeful treatment alternatives for patients who fail to respond to conventional therapies. However, individual outcomes differ because of the disease’s complexity and the influence of accompanying health conditions. Conclusions: Treating arthritis continues to be challenging due to its numerous underlying causes and the varied ways in which patients respond to treatment. Although biologics and targeted therapies have brought progress, additional research is needed to identify new treatment targets and enhance patient results. Full article
(This article belongs to the Special Issue Targeted Treatment in Chronic Inflammatory Arthritis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop